Join Dr. Marie-Laure Yaspo, Co-Founder and Chief Scientific Officer of Alacris Theranostics, as she discusses the development, application, and analysis of the Comprehensive Molecular Tumor Analysis (CMTA) test for cancer patients.

Precision oncology approaches have made great strides harnessing individual tumor mutation profiles to guide targeted therapy choices. However, deeper molecular insights are needed to improve personalized treatment decisions. Integrating gene expression analysis in personalized oncology provides an additional level of insight. These analyses include evaluating expressed mutations and drug targets, novel gene fusions, clinically relevant signatures, and the tumor immune microenvironment (TME).

Alacris Theranostics developed the Comprehensive Molecular Tumor Analysis (CMTA), a NGS-based tumor diagnostic test. The test integrates whole exome and transcriptomic sequencing (WES and RNAseq). The test deploys as an end-to-end accredited diagnostic platform from tumor sample uptake (FFPE or frozen) to personalized clinical interpretation reports.  CMTA is a tumor-agnostic test that displays a unique molecular view of each sample. CMTA is a useful approach for refractory cancers with complex patterns or tumors of unknown origin.

In this webinar, attendees will:

• Learn about the strategy implemented in Alacris’ bioinformatics pipeline to identify cancer-relevant somatic events
• Learn how Alacris uses QCI Interpret for Oncology to annotate variants and identify potential therapies
• Be eligible for a complimentary QCI Interpret demo and sample report